Encouraging The Development Of New Vaccines | Zendy

Henry G. Grabowski | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Encouraging The Development Of New Vaccines

Author(s) -

Henry G. Grabowski

Publication year - 2005

Publication title -

health affairs

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.837

H-Index - 178

eISSN - 2694-233X

pISSN - 0278-2715

DOI - 10.1377/hlthaff.24.3.697

Subject(s) - voucher , incentive , food and drug administration , investment (military) , business , public economics , key (lock) , poverty , drug development , finance , economic growth , economics , drug , medicine , risk analysis (engineering) , pharmacology , political science , computer security , accounting , politics , computer science , law , microeconomics

Investment in the development of new vaccines is suboptimal. Changing this situation requires a creative blend of "push" and "pull" strategies. One successful policy model is the Orphan Drug Act, whose key features include large research and development (R and D) tax credits as well as Food and Drug Administration (FDA) counseling and priority review. Such supply-side R and D incentive provisions can be combined with demand-side mandates and vouchers to encourage development of new vaccines. Guaranteed-purchase funds and other pull mechanisms are useful supplementary incentives in the cases of vaccines for bioterrorism and neglected diseases of poverty.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research